CEO Dugel receives new compensation package with $819,200 salary, performance stock awards

OCULAR THERAPEUTIX, INC

Base salary raised to $819,200 annually; bonus target at 75% of salary; $368,100 2024 bonus plus $500,000 special one-time bonus.
Time-Based RSU Award: 1,250,000 shares vesting over three years.
Performance Awards: PSU up to 1,500,000 shares and Performance Option for 2,750,000 shares at $7.44 strike, tied to stock price hurdles from $15 to $30.
Performance awards contingent on stockholder approval for 2021 Plan increase; no annual equity grant for 2026.
Equity awards designed to align with long-term stockholder value; service-vesting through third anniversary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.